Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 21, 2017
What is the patent landscape for Vimovo, and what generic Vimovo alternatives are available?
Vimovo is a drug marketed by Horizon Pharma Usa and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.| Patents: | 15 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 2 |
| Clinical Trials: see list | 11 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | VIMOVO at DailyMed |
| Ingredient-type | Nonsteroidal Anti-inflammatory Compounds |
| Drug Class | Nonsteroidal Anti-inflammatory Drug Proton Pump Inhibitor |
| Mechanism of Action | Cyclooxygenase Inhibitors Proton Pump Inhibitors Cytochrome P450 2C19 Inhibitors |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| naproxen and esomeprazole magnesium | Delayed-release Tablet | 375 mg/20 mg and 500 mg/20 mg | Vimovo | 11/5/2010 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,677,455 | Potassium salt of S-omeprazole | ► Subscribe | |||||||||||||||||||||||||||
| 8,206,741 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ► Subscribe | |||||||||||||||||||||||||||
| 8,466,175 | Form of S-omeprazole | ► Subscribe | |||||||||||||||||||||||||||
| 8,076,361 | Form of S-omeprazole | ► Subscribe | |||||||||||||||||||||||||||
| 6,747,155 | Process | ► Subscribe | |||||||||||||||||||||||||||
| 9,364,439 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ► Subscribe | |||||||||||||||||||||||||||
| 8,865,190 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2521391 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 2012011 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2195345 | ► Subscribe | |||||||||||||||||||||||||||
| Egypt | 21437 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | H08512315 | ► Subscribe | |||||||||||||||||||||||||||
| Austria | 291574 | ► Subscribe | |||||||||||||||||||||||||||
| Montenegro | P24908 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1273581 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 20035275 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 707580 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 00035 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| 858 | Luxembourg | ► Subscribe | 91858, EXPIRES: 20251105 | ||||||||||||||||||||||||||
| 2012000017 | Germany | ► Subscribe | PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812 | ||||||||||||||||||||||||||
| 017 | Luxembourg | ► Subscribe | 92017, EXPIRES: 20230525 | ||||||||||||||||||||||||||
| 871 | Luxembourg | ► Subscribe | 91871, EXPIRES: 20230525 | ||||||||||||||||||||||||||
| 1411900/01 | Switzerland | ► Subscribe | PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011 | ||||||||||||||||||||||||||
| 2012000051 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 | ||||||||||||||||||||||||||
| 00483 | Netherlands | ► Subscribe | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524 | ||||||||||||||||||||||||||
| 90006-4 | Sweden | ► Subscribe | PRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812 | ||||||||||||||||||||||||||
| 0 | Finland | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,728 others who get our Drug Patent Expiration Alerts:
